1. Home
  2. MIRM vs ABR Comparison

MIRM vs ABR Comparison

Compare MIRM & ABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • ABR
  • Stock Information
  • Founded
  • MIRM 2018
  • ABR 2003
  • Country
  • MIRM United States
  • ABR United States
  • Employees
  • MIRM N/A
  • ABR N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • ABR Real Estate Investment Trusts
  • Sector
  • MIRM Health Care
  • ABR Real Estate
  • Exchange
  • MIRM Nasdaq
  • ABR Nasdaq
  • Market Cap
  • MIRM 1.9B
  • ABR 2.3B
  • IPO Year
  • MIRM 2019
  • ABR 2004
  • Fundamental
  • Price
  • MIRM $39.10
  • ABR $11.03
  • Analyst Decision
  • MIRM Strong Buy
  • ABR Hold
  • Analyst Count
  • MIRM 11
  • ABR 6
  • Target Price
  • MIRM $58.55
  • ABR $12.55
  • AVG Volume (30 Days)
  • MIRM 476.2K
  • ABR 3.7M
  • Earning Date
  • MIRM 05-07-2025
  • ABR 05-02-2025
  • Dividend Yield
  • MIRM N/A
  • ABR 15.60%
  • EPS Growth
  • MIRM N/A
  • ABR N/A
  • EPS
  • MIRM N/A
  • ABR 1.18
  • Revenue
  • MIRM $336,888,000.00
  • ABR $627,518,000.00
  • Revenue This Year
  • MIRM $29.51
  • ABR N/A
  • Revenue Next Year
  • MIRM $20.27
  • ABR $9.78
  • P/E Ratio
  • MIRM N/A
  • ABR $9.35
  • Revenue Growth
  • MIRM 80.76
  • ABR N/A
  • 52 Week Low
  • MIRM $23.14
  • ABR $9.66
  • 52 Week High
  • MIRM $54.23
  • ABR $15.94
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 34.64
  • ABR 43.61
  • Support Level
  • MIRM $37.83
  • ABR $10.04
  • Resistance Level
  • MIRM $40.32
  • ABR $11.18
  • Average True Range (ATR)
  • MIRM 2.47
  • ABR 0.60
  • MACD
  • MIRM -0.33
  • ABR 0.01
  • Stochastic Oscillator
  • MIRM 25.14
  • ABR 57.32

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About ABR Arbor Realty Trust

Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment. The company is externally managed and advised by Arbor Commercial Mortgage, LLC.

Share on Social Networks: